Association of metformin with susceptibility to COVID-19 in people with Type 2 diabetes.

Like Comment
Diabetes has emerged as an important risk factor for mortality from COVID-19. Metformin, the most commonly prescribed glucose-lowering agent, has been proposed to influence susceptibility to and outcomes of COVID-19 via multiple mechanisms. We investigated whether, in patients with diabetes, metformin is associated with susceptibility to COVID-19 and its outcomes.We performed a propensity score-matched cohort study with active comparators using a large UK primary care dataset. Adults with type 2 diabetes patients and a current prescription for metformin and other glucose lowering agents (MF+) were compared to those with a current prescription for glucose-lowering agents that did not include metformin (MF-). Outcomes were confirmed COVID-19, suspected/confirmed COVID-19, and associated mortality. A negative control outcome analysis (back pain) was also performed.There were 29,558 and 10,271 patients in the MF+ and MF- groups respectively who met the inclusion criteria. In the propensity score-matched analysis, the adjusted hazard ratio for suspected/confirmed COVID-19, confirmed COVID-19, and COVID-19 related mortality were 0.85 (95%CI 0.67, 1.08), 0.80 (95%CI 0.49, 1.30), and 0.87 (95%CI 0.34, 2.20) respectively. The negative outcome control analysis did not suggest unobserved confounding.Current prescription of metformin was not associated with the risk of COVID-19 or COVID-19 related mortality. It is safe to continue prescribing metformin to improve glycaemic control in patients with diabetes, despite concerns about an impending second wave of COVID-19.


View the full article @ The Journal of clinical endocrinology and metabolism


Get PDF with LibKey

ClinOwl

The wider, wiser view for healthcare professionals. ClinOwl signposts the latest clinical content from over 100 leading medical journals.
5122 Contributions
2 Followers
0 Following

No comments yet.